Advanced Accelerator Applications (AAA), was founded in 2002, by physicist Stefano Buono, who was inspired to pursue medical applications for certain research conducted during his tenure at the European Organization for Nuclear Research, or CERN, with Nobel laureate Carlo Rubbia.
Stefano Buono founded AAA based on inspiration from his work at the European Organization for Nuclear Research (CERN).
Built first radiopharmaceutical laboratory in the Technoparc of Saint-Genis-Pouilly (France).
Achieved first Marketing Authorization to commercialize GLUSCAN® in Switzerland.
Completed construction of second radiopharmaceutical production plant in Venafro (Molise, Italy).
Completed construction of third radiopharmaceutical production plant in the Silvano Fumero Bioindustry park in Ivrea (Piedmont, Italy).
Completed construction of fourth radiopharmaceutical production plant in Troyes (France) to produce GLUSCAN® and PET Investigational Medical Products (IMP).
Completed construction of fifth radiopharmaceutical production plant in Béthune (France) to produce GLUSCAN® and PET Investigational Medical Products (IMP).
Signed exclusive license agreement with Bracco Diagnostics Inc. for distribution of CARDIOGEN-82® (Rb-82 generator for Cardiac PET) in Europe.
Completed acquisition of Gipharma, an Italian pharmaceutical contract manufacturer for injectable and freeze-dried products.
Started construction of two radiopharmaceutical production plants in Meldola (Forlì, Italy) and in “La Almunia de Doña Godina” (Zaragoza, Spain).
Signed exclusive license agreement with IASON for manufacture and distribution of F18 PET diagnostic products.
Made initial investment in Atreus Pharmaceuticals Corporation, a Canadian biopharmaceutical company headquartered in Ottawa.
Acquired BioSynthema Inc., a U.S. molecular nuclear medicine discovery company based in St. Louis, Missouri to obtain the rights to develop and commercialize LUTATHERA® (lutetium Lu 177 dotatate).
Raised €40 million from existing and new investors to advance and grow pipeline and expand PET manufacturing network.
Acquired FabOvar, a humanized monoclonal antibody fragment from Dompé.
Established third-party manufacturing agreement with GE Healthcare.
Initiated global Phase 3 study of LUTATHERA® (lutetium Lu 177 dotatate).
Established direct presence in Germany with acquisition of majority stake in Umbra medical AG, a German radiopharmaceutical company.
AAA celebrates 10-year anniversary.
Acquired fully operational PET production laboratory in Porto, Portugal.
Strengthened position in Spain with acquisition of two radiopharmaceutical companies, Barnatron and Catalana De Dispensación, S.A. (Cadisa).
Signed new third-party PET manufacturing agreements with Eli Lilly and GE Healthcare.
Entered Polish market following agreement with of Warsaw.
Completed construction of new global headquarters in Saint-Genis-Pouilly, France.
Raised €41 million to accelerate international expansion, including an increased presence in the U.S., and to support clinical trials.
Received orphan drug designation from FDA and EMA for NETSPOT® gallium Ga 68 dotatate.
Entered UK and Irish nuclear medicine markets with the acquisition of Imaging Equipment Ltd. (IEL).
Established U.S. subsidiary with an office in New York City.
Started commercial operations in 3 new production sites: Warsaw, Bonn, Marseille.
Raised €23 million in a crossover financing with U.S.-based healthcare institutions.
Announced Phase 3 NETTER-1 study evaluating LUTATHERA® (lutetium Lu 177 dotatate).
Completed $125 million Initial Public Offering and listed on the Nasdaq Global Select Market under the ticker “AAAP”.
Acquired IDB Group in The Netherlands, securing supply of lutetium 177 (Lu-177) for LUTATHERA® (lutetium Lu 177 dotatate) and future therapeutic candidates.
Signed exclusive license with Johns Hopkins for PSMA receptor ligands for prostate cancer.
Opened Expanded Access Program in the U.S. for LUTATHERA® (lutetium Lu 177 dotatate).
Expanded presence in Germany with acquisition of two production sites in Erlangen and Munich.
FDA approved NETSPOT® (gallium Ga 68 dotatate) for PET imaging.
Expanded theragnostic pipeline with NeoB, targeting GRPR receptor expressed in multiple solid tumors.
Established first U.S. distribution and manufacturing site in Millburn, New Jersey.
Raised $172.2 million from U.S.-based institutions to support ongoing operations.
European Commission approved SomaKit TOC® (gallium (Ga 68) edotreotide) for PET imaging.
Results of Phase 3 NETTER-1 study published in New England Journal of Medicine.
AAA celebrates 15-year anniversary.
CHMP Opinion Recommending Approval of LUTATHERA® (lutetium 177Lu oxodotreotide).
First clinical study with LUTATHERA® (lutetium Lu 177 dotatate) started in Japan.
European approval of LUTATHERA® (lutetium 177Lu oxodotreotide).
AAA acquired by Novartis.
FDA approval of LUTATHERA® (lutetium Lu 177 dotatate).
Signed exclusive license agreement with Cancer Targeted Technology (CTT) to develop CTT1057.
First clinical studies with PSMA-R2.
First clinical studies with NeoB.
Signed exclusive license agreement with FUJIFILM Toyama Chemical Co,. LTD to develop and commercialize radiolabeled FF-10158 for oncology indications.
Novartis successfully completes acquisition of Endocyte, Inc.
Health Canada Approval of LUTATHERA™ (lutetium 177Lu oxodotreotide).
European approval of LysaKare® for reduction of kidney exposure to radiation during PRRT with LUTATHERA® (lutetium 177Lu oxodotreotide).
State of Israel Ministry of Health Approval for Lutathera® (lutetium 177Lu oxodotreotide).
Swissmedic approval for LUTATHERA® (lutetium 177Lu oxodotreotide).
Health Canada Approval of NETSPOT®(gallium (68Ga) oxodotreotide).